Radiopharmaceuticals startup RayzeBio submits IPO pitch, foreshadowing expected post-Labor Day bump in biotech listings
A Phase III-stage radiopharmaceuticals biotech has filed to go public a little over a week before bankers and industry watchers expect a slight post-Labor Day bump in biotech IPO pitches.
After having raised $418 million privately, the San Diego startup RayzeBio hopes to gain a spot on the Nasdaq and trade as “RYZB,” per an S-1 filing from Thursday evening.
RayzeBio is likely one of a few drug developers that will go public before year’s end; Jordan Saxe, Nasdaq’s head of healthcare listings, told Endpoints News last month that the exchange anticipates another five to 10 before New Year’s. Biotechs will look to pounce on any window they can get in this market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.